Money Info Investment News Show
The December 1st show features a live interview with:
Dr Gloria Herndon
and Dr Jay Ellenby
Discussing recent immune therapies advancements at
Immune Therapeutics Inc.
(Stock Symbol: IMUN),
Visit The Corporate Site — ImmuneTherapeutics.com
See Corporate Investors Information and stock quote page: Click Here
Listen To Interview Replay:
Listen To Full Show Replay:
Immune Therapeutics is a specialty pharmaceutical company involved in the manufacturing, distribution and marketing of our novel patented therapies to combat chronic, life-threatening diseases through the activation and modulation of the body’s immune system. The Company’s technology platform is built on two different immunotherapies, Low Dose Naltrexone (LDN) and Methionine-Enkephalin (MENK).
Both therapies have been decades in the making at institutions such as the Pennsylvania State University Medical School at Hershey, University of Chicago, State University of New York, and Multiple Sclerosis Center at UCSF. These efforts were pioneered by leading immunologists: Dr. Nicholas Plotnikoff, Dr. Ronald Herberman, Dr. Bernard Bihari, Ian S. Zagon, Dr. Jill Smith, Patricia McLaughlin, and Dr. Jaquelyn McCandless.
Immune Therapeutics has spent the last two years acquiring regulatory approval in emerging and developing nations for LDN marketed under the brand name Lodonal™. Lodonal™ is a highly innovative immunotherapy for the treatment of autoimmune diseases, HIV/AIDS, opportunistic infections, cancer and a range of other serious diseases. Our proprietary Opiate and T Cell Receptor technology exploits the power of the body’s own immune system to find and kill diseased cells.
Low Dose Naltrexone used as an immune modulator
Low Dose Naltrexone as it is known in the United States, or Lodonal as it is known internationally, has its origins in the FDA approved 50mg Naltrexone. Originally used to treat opiate dependences, the Immune Therapeutics patented treatments, which cover a wide range of indications (link to LDN patents), is currently used as an immune modulator. See Report — Click Here
Undervalued Medical Stocks
The biotechnology company working to combat chronic, life-threatening diseases through the activation and modulation of the body’s immune system using our patented immunotherapy. Their Products and immunotherapy technologies are designed to harness the power of the immune system to improve the treatment of cancer, infections such as HIV/AIDS, chronic inflammatory diseases, and autoimmune diseases. The company’s therapies have been demonstrated over time to be highly efficacious and virtually free of side negative effects.
Small Cap Medical Stock News
Immune Therapeutics Adds Experienced New Board Member Saiid Zarrabian — October 7, 2015
Partnership with GB Pharma and AHAR sign LOI with Fidson Healthcare Plc for the distribution of Lodonal in Nigeria Announced.
Immune Therapeutics Inc. in partnership with GB Pharma Holdings Inc and American Hospitals & Resort [AHAR], announces that they have signed a Letter of Intent with Nigerian public company, Fidson Healthcare Plc [NSE:FIDSON.LG] one of Nigeria’s leading pharmaceutical companies. — See News
Immune Therapeutics Inc, Announces the official publication announcement of the NAFDAC approved 90-Day Bridging Trial of Lodonal™ with HIV/AIDS Patients.
Immune Therapeutics Inc – Lodonal™ an Adjunct Immune Therapy for Treatment of Patients with HIV/AIDS
Money Info Investment News Show Airs
10 AM to 11 AM EDT
Use this Link To Watch The Show:
Be On The Air With Us
Call In Your Questions
The Princeton Research Money Info show features where to invest now, stock market, business, economy and financial investment news.
The show is broadcast live on the internet and on the air from the studios of Radio Station WPSL AM 1590, Port St. Lucie, Florida — The Talk of the Treasure Coast
Money Info is hosted by investing experts Mike King and Charles Moskowitz together with radio broadcasting professional Greg Wyatt.